Research programme: hepatitis C virus therapy - Vernalis

Drug Profile

Research programme: hepatitis C virus therapy - Vernalis

Alternative Names: Hepatitis C virus therapy research programme - Vernalis

Latest Information Update: 07 Oct 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vernalis
  • Class
  • Mechanism of Action Hepatitis C virus replication inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Oct 2004 Discontinued - Preclinical for Hepatitis C in United Kingdom (unspecified route)
  • 03 Oct 2003 RiboTargets has been integrated into British Biotech, which has merged with Vernalis Group to form Vernalis
  • 19 May 2003 RiboTargets has been acquired by British Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top